{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:17:58Z","timestamp":1787509078601,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017559","name":"Recordati Rare Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11154-026-10020-1","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:23:36Z","timestamp":1772238216000},"page":"201-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of osilodrostat in a block-and-replace and titration strategy for cushing\u2019s syndrome: a position paper by French experts"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-8800","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Castinetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Bertherat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Raverot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Tabarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"10020_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3803\/EnM.2024.501","volume":"40","author":"L Guignat","year":"2025","unstructured":"Guignat L, Bertherat J. Medical treatment of cushing\u2019s syndrome. Endocrinol Metab (Seoul). 2025;40:26\u201338.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10020_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/cen.14014","volume":"91","author":"S Wengander","year":"2019","unstructured":"Wengander S, Trimpou P, Papakokkinou E, Ragnarsson O. The incidence of endogenous Cushing\u2019s syndrome in the modern era. Clin Endocrinol (Oxf). 2019;91:263\u201370.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10020_CR3","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40618-022-01754-1","volume":"45","author":"G Giuffrida","year":"2022","unstructured":"Giuffrida G, Crisafulli S, Ferra\u00f9 F, Fontana A, Alessi Y, Calapai F, et al. Global cushing\u2019s disease epidemiology: a systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2022;45:1235\u201346.","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"10020_CR4","doi-asserted-by":"publisher","first-page":"bvaf027","DOI":"10.1210\/jendso\/bvaf027","volume":"9","author":"M Fleseriu","year":"2025","unstructured":"Fleseriu M, Auchus RJ, Bancos I, Biller BMK. Osilodrostat treatment for adrenal and ectopic Cushing syndrome: integration of clinical studies with case presentations. J Endocr Soc. 2025;9(4):bvaf027.","journal-title":"J Endocr Soc"},{"issue":"8","key":"10020_CR5","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1210\/clinem\/dgac265","volume":"107","author":"P Limumpornpetch","year":"2022","unstructured":"Limumpornpetch P, Morgan AW, Tiganescu A, Baxter PD, Nyawira Nyaga V, Pujades-Rodriguez M, et al. The effect of endogenous Cushing syndrome on all-cause and cause-specific mortality. J Clin Endocrinol Metab. 2022;107(8):2377\u201388.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10020_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1530\/EJE-11-0272","volume":"165","author":"E Valassi","year":"2011","unstructured":"Valassi E, Santos A, Yaneva M, T\u00f3th M, Strasburger CJ, Chanson P, et al. The European Registry on Cushing\u2019s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011;165(3):383\u201392.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10020_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11102-023-01343-2","volume":"26","author":"A Mondin","year":"2023","unstructured":"Mondin A, Ceccato F, Voltan G, Mazzeo P, Manara R, Denaro L, et al. Complications and mortality of Cushing\u2019s disease: report on data collected over a 20-year period at a referral centre. Pituitary. 2023;26(5):551\u201360.","journal-title":"Pituitary"},{"issue":"4","key":"10020_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/ejendo\/lvaf059","volume":"192","author":"A Akirov","year":"2025","unstructured":"Akirov A, Fleseriu M, Masri-Iraqi H, Shochat T, Kushnir S, Shimon I, et al. Mortality in cushing\u2019s syndrome: declining over 2 decades but remaining higher than the general population. Eur J Endocrinol. 2025;192(4):445\u201355.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10020_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847\u201375.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10020_CR10","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BMK, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. Treatment of Cushing\u2019s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10020_CR11","doi-asserted-by":"publisher","first-page":"101490","DOI":"10.1016\/j.beem.2021.101490","volume":"35","author":"EV Varlamov","year":"2021","unstructured":"Varlamov EV, Han AJ, Fleseriu M. Updates in adrenal steroidogenesis inhibitors for Cushing\u2019s syndrome - a practical guide. Best Pract Res Clin Endocrinol Metab. 2021;35(1):101490.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"10020_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11060-024-04670-x","volume":"168","author":"C Capatina","year":"2024","unstructured":"Capatina C, Hanzu FA, Hinojosa-Amaya JM, Fleseriu M. Medical treatment of functional pituitary adenomas, trials and tribulations. J Neurooncol. 2024;168(2):197\u2013213.","journal-title":"J Neurooncol"},{"issue":"10","key":"10020_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2174\/0113816128290025240216110928","volume":"30","author":"E Divaris","year":"2024","unstructured":"Divaris E, Kostopoulos G, Efstathiadou ZA. Current and emerging pharmacological therapies for cushing\u2019s disease. Curr Pharm Des. 2024;30(10):757\u201377.","journal-title":"Curr Pharm Des"},{"issue":"6","key":"10020_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11102-022-01268-2","volume":"25","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Biller BMK. Treatment of cushing\u2019s syndrome with osilodrostat: practical applications of recent studies with case examples. Pituitary. 2022;25(6):795\u2013809.","journal-title":"Pituitary"},{"issue":"7","key":"10020_CR15","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1210\/clinem\/dgab122","volume":"106","author":"F Castinetti","year":"2021","unstructured":"Castinetti F, Nieman LK, Reincke M, Newell-Price J. Approach to the patient treated with steroidogenesis inhibitors. J Clin Endocrinol Metab. 2021;106(7):2114\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10020_CR16","doi-asserted-by":"publisher","first-page":"102908","DOI":"10.1016\/j.arcmed.2023.102908","volume":"54","author":"F Castinetti","year":"2023","unstructured":"Castinetti F. Pharmacological treatment of Cushing\u2019s syndrome. Arch Med Res. 2023;54(8):102908.","journal-title":"Arch Med Res"},{"issue":"4","key":"10020_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/cen.14551","volume":"98","author":"F Castinetti","year":"2023","unstructured":"Castinetti F, Amodru V, Brue T. Osilodrostat in cushing\u2019s disease: the risk of delayed adrenal insufficiency should be carefully monitored. Clin Endocrinol (Oxf). 2023;98(4):629\u201330.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10020_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.12703\/r\/12-6","volume":"12","author":"M Markou","year":"2023","unstructured":"Markou M, Lavrentaki A, Ntali G. Recent advances in understanding and managing pituitary adenomas. Fac Rev. 2023;12:6.","journal-title":"Fac Rev"},{"issue":"3","key":"10020_CR19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4103\/ijem.ijem_260_23","volume":"28","author":"L Nagendra","year":"2024","unstructured":"Nagendra L, Dutta D, Raizada N, Surana V, Selvan C, Bhattacharya S. Efficacy and safety of Osilodrostat in managing cushing\u2019s syndrome: a systematic review and meta-analysis. Indian J Endocrinol Metab. 2024;28(3):232\u20138.","journal-title":"Indian J Endocrinol Metab"},{"issue":"9","key":"10020_CR20","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, et al. Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 2020;8(9):748\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"10020_CR21","doi-asserted-by":"publisher","first-page":"A516","DOI":"10.1210\/jendso\/bvab048.1055","volume":"5","author":"M Gadelha","year":"2021","unstructured":"Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A, et al. Osilodrostat is an effective and Well-Tolerated treatment for cushing\u2019s disease (CD): results from a phase III study with an Upfront, Randomized, Double-Blind, Placebo-Controlled phase (LINC 4). J Endocr Soc. 2021;5(Suppl 1):A516\u20137.","journal-title":"J Endocr Soc"},{"issue":"7","key":"10020_CR22","doi-asserted-by":"publisher","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","volume":"107","author":"M Gadelha","year":"2022","unstructured":"Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A, et al. Randomized trial of Osilodrostat for the treatment of Cushing disease. J Clin Endocrinol Metab. 2022;107(7):e2882\u201395.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10020_CR23","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-20-0352","volume":"183","author":"J Newell-Price","year":"2020","unstructured":"Newell-Price J, Nieman LK, Reincke M, Tabarin A. Endocrinology in the time of COVID-19: management of cushing\u2019s syndrome. Eur J Endocrinol. 2020;183(1):G1\u20137.","journal-title":"Eur J Endocrinol"},{"key":"10020_CR24","unstructured":"Metaplan. Metaplan basic techniques. Available at: https:\/\/www.metaplan.com\/wp-content\/uploads\/2021\/04\/Metaplan_Basiswissen_engl.pdf. Accessed 26 Jul 2025."},{"key":"10020_CR25","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae864","author":"A Ferriere","year":"2024","unstructured":"Ferriere A, Nunes ML, Tabarin A. Approach to the patient with cyclical Cushing syndrome. J Clin Endocrinol Metab. 2024. https:\/\/doi.org\/10.1210\/clinem\/dgae864.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10020_CR26","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1210\/clinem\/dgac691","volume":"108","author":"A Dormoy","year":"2023","unstructured":"Dormoy A, Haissaguerre M, Vitellius G, Do Cao C, Geslot A, Drui D, et al. Efficacy and safety of Osilodrostat in paraneoplastic Cushing syndrome: A Real-World multicenter study in France. J Clin Endocrinol Metab. 2023;108(6):1475\u201387.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10020_CR27","doi-asserted-by":"publisher","first-page":"K29","DOI":"10.1093\/ejendo\/lvad060","volume":"188","author":"J Poirier","year":"2023","unstructured":"Poirier J, Bonnet-Serrano F, Thomeret L, Bouys L, Bertherat J. Prolonged adrenocortical blockade following discontinuation of osilodrostat. Eur J Endocrinol. 2023;188(6):K29\u201332.","journal-title":"Eur J Endocrinol"},{"key":"10020_CR28","doi-asserted-by":"publisher","first-page":"1629387","DOI":"10.3389\/fmed.2025.1629387","volume":"12","author":"L Dzialach","year":"2025","unstructured":"Dzialach L, Respondek W, Siejka A, Witek P. Prolonged adrenal suppression after osilodrostat discontinuation in a patient with Cushing\u2019s disease with eventual hypercortisolism relapse: case report and literature review. Front Med (Lausanne). 2025;12:1629387.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"10020_CR29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1507\/endocrj.EJ19-0617","volume":"67","author":"T Tanaka","year":"2020","unstructured":"Tanaka T, Satoh F, Ujihara M, Midorikawa S, Kaneko T, Takeda T, et al. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11\u03b2-hydroxylase inhibitor, in Japanese patients with endogenous cushing\u2019s syndrome other than cushing\u2019s disease. Endocr J. 2020;67(8):841\u201352.","journal-title":"Endocr J"},{"issue":"1","key":"10020_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","volume":"6","author":"A Lacroix","year":"2018","unstructured":"Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, et al. Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol. 2018;6(1):17\u201326.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10020_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0306-4530(00)00057-3","volume":"26","author":"AA Stone","year":"2001","unstructured":"Stone AA, Schwartz JE, Smyth J, Kirschbaum C, Cohen S, Hellhammer D, et al. Individual differences in the diurnal cycle of salivary free cortisol: a replication of flattened cycles for some individuals. Psychoneuroendocrinology. 2001;26(3):295\u2013306.","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"10020_CR32","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ando.2016.05.002","volume":"77","author":"V Raverot","year":"2016","unstructured":"Raverot V, Richet C, Morel Y, Raverot G, Borson-Chazot F. Establishment of revised diagnostic cut-offs for adrenal laboratory investigation using the new Roche diagnostics Elecsys\u00ae cortisol II assay. Ann Endocrinol (Paris). 2016;77(5):620\u20132.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"10020_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2265.2004.02106.x","volume":"61","author":"PM Mah","year":"2004","unstructured":"Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2004;61(3):367\u201375.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10020_CR34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1530\/EJE-22-0317","volume":"187","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Newell-Price J, Pivonello R, Shimatsu A, Auchus RJ, Scaroni C, et al. Long-term outcomes of osilodrostat in Cushing\u2019s disease: LINC 3 study extension. Eur J Endocrinol. 2022;187(4):531\u201341.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10020_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11102-020-01097-1","volume":"24","author":"C Fontaine-Sylvestre","year":"2021","unstructured":"Fontaine-Sylvestre C, L\u00e9tourneau-Guillon L, Moumdjian RA, Berthelet F, Lacroix A. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent cushing\u2019s disease. Pituitary. 2021;24(2):207\u201315.","journal-title":"Pituitary"},{"issue":"3","key":"10020_CR36","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-20-1088","volume":"184","author":"M Reincke","year":"2021","unstructured":"Reincke M, Albani A, Assie G, Bancos I, Brue T, Buchfelder M, et al. Corticotroph tumor progression after bilateral adrenalectomy (Nelson\u2019s syndrome): systematic review and expert consensus recommendations. Eur J Endocrinol. 2021;184(3):P1\u201316.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10020_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1530\/EJE-22-0208","volume":"187","author":"F Bonnet-Serrano","year":"2022","unstructured":"Bonnet-Serrano F, Poirier J, Vaczlavik A, Laguillier-Morizot C, Blanchet B, Baron S, et al. Differences in the spectrum of steroidogenic enzyme inhibition between osilodrostat and metyrapone in ACTH-dependent Cushing syndrome patients. Eur J Endocrinol. 2022;187(2):315\u201322.","journal-title":"Eur J Endocrinol"},{"key":"10020_CR38","doi-asserted-by":"publisher","first-page":"1236465","DOI":"10.3389\/fendo.2023.1236465","volume":"14","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Snyder PJ, Witek P, Bex M, Belaya Z, Turcu AF, et al. Long-term efficacy and safety of osilodrostat in patients with Cushing\u2019s disease: results from the LINC 4 study extension. Front Endocrinol (Lausanne). 2023;14:1236465.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"10020_CR39","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1093\/humrep\/dead187","volume":"38","author":"GE Papadakis","year":"2023","unstructured":"Papadakis GE, de Kalbermatten B, Dormoy A, Salenave S, Trabado S, Vieira-Pinto O, et al. Impact of Cushing\u2019s syndrome on the gonadotrope axis and testicular functions in men. Hum Reprod. 2023;38(12):2350\u201361.","journal-title":"Hum Reprod"},{"issue":"1","key":"10020_CR40","doi-asserted-by":"publisher","first-page":"bvae201","DOI":"10.1210\/jendso\/bvae201","volume":"9","author":"J Newell-Price","year":"2024","unstructured":"Newell-Price J, Fleseriu M, Pivonello R, Feelders RA, Gadelha MR, Lacroix A, et al. Improved clinical outcomes during long-term osilodrostat treatment of Cushing disease with normalization of late-night salivary cortisol and urinary free cortisol. J Endocr Soc. 2024;9(1):bvae201.","journal-title":"J Endocr Soc"},{"issue":"12","key":"10020_CR41","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1210\/clinem\/dgaf206","volume":"110","author":"D Ferrari","year":"2025","unstructured":"Ferrari D, Bonaventura I, Simeoli C, Tomaselli A, Vincenzi L, De Alcubierre D, et al. Chronotherapy with once-daily osilodrostat improves cortisol rhythm, quality of life, and sleep in Cushing\u2019s syndrome. J Clin Endocrinol Metab. 2025;110(12):3525\u201337.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-026-10020-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-026-10020-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-026-10020-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:22:15Z","timestamp":1778592135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-026-10020-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10020"],"URL":"https:\/\/doi.org\/10.1007\/s11154-026-10020-1","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A formal approval of this paper was not required according to French legislation, as the present position paper involved no intervention and relied solely on the collection of non-invasive data such as interviews and virtual meetings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors gave their consent to the submission and publication of the present manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Antoine Tabarin received Honorarium for boards and conferences from Recordati rare diseases, Esteve, Pfizer, Lundbeck, Crinetics and Recordati rare diseases. Jerome Bertherat received consulting honoraria (consulting, lectures, and\/or meeting attendance) from HRA Pharma, Recordati Rare Diseases, Crinetics.Jacques Young received honorarium for boards and conferences from Recordati rare diseases, Esteve, Pfizer.Frederic Castinetti received research grants and honoraria from Recordati, Esteve and Lundbeck.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registration number"}}]}}